Literature DB >> 2593834

Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements.

D J Barton1, M D Ludman, K Benkov, G A Grabowski, N S LeLeiko.   

Abstract

The resting energy expenditure (REE; kcal/d) of 25 patients with Gaucher's disease type 1 was determined by indirect calorimetry. The average observed REE for the group was approximately 44% greater (P less than .01) than that predicted (predicted REE) for these patient's age, sex, height, and weight. The increased caloric requirements of these patients was manifested by a height-for-age less than or equal to the fifth percentile in seven of nine growing children and a muscle mass of less than the fifth percentile in 15 of 19 patients studied. The excess REE (observed REE--predicted REE) for individual Gaucher's disease type 1 patients was directly related to their liver volume as estimated from radionuclide scans and to the mass of the spleen as measured at splenectomy. The relationship between spleen mass and excess REE was demonstrated by an average 22.0% decrease in REE following splenectomy in five patients. Based on these data, the metabolic rate of the splenic tissue removed from the patients was calculated to be 96.8 kcal/d/kg, about twofold to threefold less than that of normal splenic tissue. These findings indicate that the elevated REE observed in these patients resulted from the large mass of Gaucher's cells, which although individually hypometabolic, were cumulatively an excessive metabolic burden. Furthermore, they suggest that indirect calorimetry may be a quantitative tool for measuring disease progression and the effect of therapeutic intervention in Gaucher's disease type 1.

Entities:  

Mesh:

Year:  1989        PMID: 2593834     DOI: 10.1016/0026-0495(89)90165-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Protein, glucose and energy metabolism in Gaucher disease type I.

Authors:  O A Bodamer; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

Review 2.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 3.  Sphingolipids: the nexus between Gaucher disease and insulin resistance.

Authors:  Maria Fuller
Journal:  Lipids Health Dis       Date:  2010-10-11       Impact factor: 3.876

Review 4.  Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements.

Authors:  Gregory A Grabowski; Generoso Andria; Antonio Baldellou; Pauline E Campbell; Joel Charrow; Ian J Cohen; Chris M Harris; Paige Kaplan; Eugen Mengel; Miguel Pocovi; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

5.  Assessment of Basal Metabolic Rate and Nutritional Status in Patients with Gaucher Disease Type III.

Authors:  Divair Doneda; Filippo P Vairo; André L Lopes; Alvaro Reischak-Oliveira; Pedro Schestatsky; Marino M Bianchin; Cileide C Moulin; Ida V D Schwartz
Journal:  JIMD Rep       Date:  2013-12-17

6.  Genetic and clinical characteristics of Filipino patients with Gaucher disease.

Authors:  Mary Anne D Chiong; Marie Julianne C Racoma; Mary Ann R Abacan
Journal:  Mol Genet Metab Rep       Date:  2018-04-05

7.  Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment.

Authors:  Paola Iaccarino Idelson; Enza Speranza; Maurizio Marra; Fabrizio Pasanisi; Rosa Sammarco; Ferruccio Galletti; Pasquale Strazzullo; Antonio Barbato
Journal:  Nutrients       Date:  2022-08-03       Impact factor: 6.706

8.  Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review.

Authors:  Divair Doneda; Cristina B Netto; Cileide C Moulin; Ida Vanessa D Schwartz
Journal:  Nutr Metab (Lond)       Date:  2013-04-09       Impact factor: 4.169

9.  Fetal gene therapy for neurodegenerative disease of infants.

Authors:  Giulia Massaro; Citra N Z Mattar; Andrew M S Wong; Ernestas Sirka; Suzanne M K Buckley; Bronwen R Herbert; Stefan Karlsson; Dany P Perocheau; Derek Burke; Simon Heales; Angela Richard-Londt; Sebastian Brandner; Mylene Huebecker; David A Priestman; Frances M Platt; Kevin Mills; Arijit Biswas; Jonathan D Cooper; Jerry K Y Chan; Seng H Cheng; Simon N Waddington; Ahad A Rahim
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.